We audited records of Ph +ve ALL paediatric patients diagnosed between January 2005-December 2014 who underwent treatment with institutional ALL protocol (MCP-841) with or without Imatinib. No patient underwent SCT. EFS was calculated from date of diagnosis to date of relapse/progression while OS was calculated from date of diagnosis to date of last follow up. Results: A total of 104 patients were diagnosed with Ph+ ALL. The median age 11 years vs 7.9 years, Male:Female ratio of 4:1 vs 2:1 and median WBC count 88,000 cells/mm3 vs 40,514 cells/mm3 was higher compared to west. Similarly CNS involvement: 4 were CNS II (5%) and15 were CNS III (20%) was higher compared to 6% in west. Also, 86% children had NCI highrisk disease compared to 60% in west. Of 94 patients who started therapy at our centre, 72 patients received Imatinib during their treatment: 29 during induction and 43 post-induction. Fourteen did not receive Imatinib and 8 abandoned therapy before response evaluation. Median overall survival (OS) of the entire cohort was 18 months and estimated 5-year OS and EFS was 29% and 23% respectively. OS for patients who received Imatinib at any time during therapy was 38%. However, none of the patients who did not get Imatinib survived for 3 years. Five-year EFS in patients who received Imatinib in induction was significantly worse at 23% compared to 34% for those who started it post-induction (p¼0.03). However, there was no statistical difference in toxic deaths and morphologic remissions between the groups. The 5-year overall survival of NCI low-risk group 57% compared to 24% in NCI-high risk group. Conclusion: Ph+ ALL is more common in India and presents with higher age and white cell count, as well as high prevalence of CNS involvement and NCI high-risk disease. Outcome of Ph+ALL without Imatinib and stem cell transplantation is dismal. Combined therapy including aggressive chemotherapy and Imatinib improves outcome but outcome of NCI-High risk disease is suboptimal. Background: Majority of mature B-ALL blasts express B lymphocyte antigen (CD20) on their surface however, only 30-50% of B-cell precursor ALL blasts express CD20. The incongruous expression of CD20 in BCP-ALL patients and its prognostic relevance has been reported in adult and pediatric cases but with discrepant results. In view of this we aimed to determine the prognostic impact of CD20 expression in pediatric BCP-ALL patients treated at our department. Aim of the study: To investigate and correlate the expression profile of CD20 in precursor B-cell ALL patients with treatment outcome. Methodology: Mononuclear cells were isolated using ficoll-histopaque layering technique from bone marrow (BM)/peripheral blood (PB) samples. Immunophenotyping of blast cells at diagnosis was done by multiparametric flow cytometry. Expression of antigens on leukemic cells was determined by using a 6-dimensional space formed by 2 light scatter parameters (forward scatter [FSC] and side scatter [SSC]) and 4 fluorescenceassociated characteristics. The existence of blast cell population was established on the basis of abnormal antigen expression profiles of the blasts as compared to the control. Results: A total of 65 pediatric patients (median age 9 yrs, range 1-17 yrs; M: F 4:1; median TLC-17.4x10 9 /l, range 1.1-715x10 9 /l) were studied. CD20 positivity was defined as more than 20% of leukemia blasts expressing surface CD20. Expression of CD20 was present in 37/65 (57%) patients with BCP ALL. A worse outcome has been observed in our patients expressing CD20 than those without the expression. Disease free survival at 20 months in CD20-positive and CD20-negative groups (33% [95% CI, 10-54] versus 89% [95% CI, 54-96], P¼0.002) was statistically significant. Overall survival at 18 months (46% [95% CI, 26-61] versus 65% [95% CI, 40-78], P¼0.01) was also poorer in CD20-positive group than CD20-negative group.
Background: Majority of mature B-ALL blasts express B lymphocyte antigen (CD20) on their surface however, only 30-50% of B-cell precursor ALL blasts express CD20. The incongruous expression of CD20 in BCP-ALL patients and its prognostic relevance has been reported in adult and pediatric cases but with discrepant results. In view of this we aimed to determine the prognostic impact of CD20 expression in pediatric BCP-ALL patients treated at our department. Aim of the study: To investigate and correlate the expression profile of CD20 in precursor B-cell ALL patients with treatment outcome. Methodology: Mononuclear cells were isolated using ficoll-histopaque layering technique from bone marrow (BM)/peripheral blood (PB) samples. Immunophenotyping of blast cells at diagnosis was done by multiparametric flow cytometry. Expression of antigens on leukemic cells was determined by using a 6-dimensional space formed by 2 light scatter parameters (forward scatter [FSC] and side scatter [SSC] ) and 4 fluorescenceassociated characteristics. The existence of blast cell population was established on the basis of abnormal antigen expression profiles of the blasts as compared to the control. Results: A total of 65 pediatric patients (median age 9 yrs, range 1-17 yrs; M: F 4:1; median TLC-17.4x10 9 /l, range 1.1-715x10 9 /l) were studied. CD20 positivity was defined as more than 20% of leukemia blasts expressing surface CD20. Expression of CD20 was present in 37/65 (57%) patients with BCP ALL. A worse outcome has been observed in our patients expressing CD20 than those without the expression. Disease free survival at 20 months in CD20-positive and CD20-negative groups (33% [95% CI, Introduction: Plasmablastic lymphoma is a rare form of non Hodgkin lymphoma. Little data exists on its epidemiology and outcome in children. We aimed to study the clinical, epidemiological profile and outcome of plasmablastic lymphoma in our centre. Methods and materials: This is a retrospective analysis of 10 years data from January-2006 to December-2015 at Tata Memorial Centre, Mumbai. Analysis included all children who presented to our hospital during this period and diagnosed to have plasmablastic lymphoma by histopathology and immunohistochemistry. Patients received various multiagent chemotherapeutic regimens. The outcome of these patients was analyzed. Results: Thirteen cases of pediatric plasmablastic lymphoma were diagnosed and treated in our center during the study period. Eleven were male and 2 female. Median age at diagnosis was 12 years (Range1-15 years). HIV infection was detected in all except 3 children. Four patients had B symptoms at presentation. Various sites of involvement at diagnosis were lymph nodes (9 patients), paranasal sinuses (7 patients), bone (4 patients), pleura (1 patient), orbit (1 patient) and soft tissue (1 patient). Bone marrow and CSF were involved in 5 and 2 patients respectively, while 2 patients had involvement of both. Patients were given various multi agent chemotherapeutic regimens like MCP-842, CVEP (Cyclophosphamide, Vincrstine, Etoposide, Prednisolone), EPOCH (Etoposide, Prednisolone, Vincristine, Cyclophosphamide, Adriamycin) and oral metronomic chemotherapy (6-Thioguanine, Etoposide). All patients with HIV infection also received antiretroviral therapy. At last follow up, 4 patients were disease free, 6 patients died of disease progression, 1 patient died of cause unrelated to disease and 2 patients lost to follow up (one patient HIV positive and one HIV negative). Conclusion: Plasmablastic lymphoma is an aggressive non Hodgkin lymphoma in children. Majority of cases are HIV positive and present with disseminated disease. The most common sites of involvement include lymph nodes and paranasal sinuses. Despite intensive chemotherapy outcome is poor. Intervention: Treated with anthracycline-based induction (mitoxantrone 12 mg/m2/day x 3 doses +cyatarabine 100 mg/m2/dose 12 hrly d1 to d10, daunorubicin 50 mg/m2/day x 3 doses +cyatarabine), followed by consolidation with 2 cycles of high-dose (3g/m2) cyatarabine. Stem cell transplantation was not performed. Analysis: Data extracted from the medical records. Patient identity was masked. Kaplan-Meier method was used for survival analysis. Outcome: i. Proportion of cases achieving remission ii. Event free survival (EFS) Result: Of the 39 children presenting to the centre, 27 (69.2%) received treatment. Twenty-five (92.5%) received mitoxantrone in induction. Median age was 11.1 years (range:1.08-17.1) with a slight female preponderance (F:M¼1.2:1). Median follow-up was 16 months (range: 5-23). Most common reason for treatment-refusal was financial constraint. The major presenting complaints included fever (100%) patients and bleeding manifestations (66.7%). Rare presentations include paraparesis (epidural mass on MRI spine), bilateral proptosis (one case each). No patient had CNS disease. WBC count was 13,600 (range: 600-3,56,000). Hyperleucocytosis was documented in 3 patients (11%). The most frequent genetic abnormality was t (8;21). 22.2% had a normal karyotype. Patients in standard (SR), intermediate (IR), and high-risk (HR) groups were 10 (37.1%), 11 (40.7%) and 6 (22.2%), respectively Complete remission was achieved in 76.9% after induction-1, and 80.8% after induction-2. Two (7.4%) children had refractory disease. Both had received daunorubicin-based induction. Other events included 6 non relapse deaths (22.5%). Of these 5 were toxicity-related deaths (18.5%, 2 deaths in CR), and 1 death due to intracranial bleed (3.5%). 5 patients relapsed (18.5%). Event free survival (EFS) at 2.5 years was 52 %. EFS of SR, IR, HRgroup was 80%, 45.5% and 16.7% respectively. Commonest cause of non-relapse mortality was multidrug-resistant sepsis (5/9 deaths), with Klebsiella pneumoniae (n¼4/5, 80%) being the commonest isolate. Conclusion: Complete remission and relapse rates were comparable to that reported from developed countries; however, these were partly offset by higher toxicity-related deaths. Favourable outcome was noted in the standard-risk group. Feasibility of a mitoxantrone-based induction protocol was demonstrated, and plausibly contributed to the favourable outcome. Support for equitable access to healthcare, conformity to a standard protocol, and optimization of supportive care, would help us further improve outcomes.
LM-1_V1.12 DETECTION OF THE THREE FUSION ONCOGENES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA e SINGLE CENTRE EXPERIENCE
G. Krishna Sameera, Julius Scott, Tina Koshy, M.S. Latha. Sri Ramchandra Univeristy, India Background/Objectives:
Chromosomal abnormalities, such as t(9;22)(q34;q11) (ABL/BCR), t(12;21)(p13;q22) (TEL/AML1), and t(11q23) (MLL) are independent prognostic indicators in childhood acute lymphoblastic leukemia resulting in risk adapted therapy. Accurate and rapid detection of these abnormalities is mandatory, which is achieved by karyotyping, fluorescence in situ hybridization (FISH), and real time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR). Risk stratification helps in improving the survival rates and the lack of adequate and appropriate diagnostic facilities in developing countries are identified as one of the causes of low survival rates. Design/Methods: The aim of thr study was to identify the incidence of common fusion oncogenes of childhood acute lymphoblastic leukemia and to assess the sensitivity and specificity of the tests used to identify the fusion oncogenes.The study was conducted on 35 patients being treated for ALL in our institution. Diagnostic tests of karyotyping, FISH and RT-PCR were performed according accepted protocols and standards.Study was approved by institution ethics committee and funded by GATE project of SRU. Results: The frequency of t(9;22)(q34;q11) (BCR/ABL), t(12;21)(p13;q22) (TEL/AML1), and t(11q23) (MLL) was found to be 3%,6% and 2% respectively.The adopted diagnostic techniques had a high-individual diagnostic accuracy in detecting the above-mentioned chromosomal translocations.
However, the sensitivity of karyotyping for detecting the TEL-AML1 fusion gene and MLL-rearrangements was low. Conclusion: Despite the high-diagnostic accuracy, all diagnostic techniques should be used complementary, because any detection of a significant chromosomal aberration irrespective of diagnostic mode has to be considered in therapy. However, a larger study population would establish the diagnostic accuracy of the three techniques as well as the frequency of these genetic alterations in children with ALL.
